Optimization of modulators of Gbg-SNARE interaction

Gbg-SNARE 相互作用调制器的优化

基本信息

  • 批准号:
    8697750
  • 负责人:
  • 金额:
    $ 40.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Release of chemical transmitters by regulated exocytosis underlies many forms of intercellular communication, including hormone release and synaptic transmission. Exocytosis is subject to complex modulation and involves a web of protein-protein interactions and membrane remodeling events. G protein-coupled receptors (GPCRs) play a central role in orchestrating this complex regulation, and Gi/o- coupled GPCRs are well known to inhibit transmitter release from neurosecretory cells by release of G protein ¿? subunits. This profound inhibition has the potential to contribute to presynaptic integration and synaptic plasticity. The best-studied mechanism for this inhibition is modulation of the voltage sensitivity of Ca2+ channels. However, G¿? can also directly inhibit neurotransmitter release at a point distal to Ca2+ entry by binding to soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins as well as the assembled SNARE complex. We have shown that the C-terminus of SNAP25 is critical for the ability to inhibit transmitter release. We have devised an assay of G¿?-SNAP25 interaction using the AlphaScreen, and have screened a small library of compounds that were designed based on known chemotypes which modulate protein-protein interaction (PPI) for both inhibitors and enhancers of this. In this grant, we will optimize both inhibitors and enhancers of G¿?-SNAP25 interaction In Aim 1, we will carry out medicinal chemical optimization of both classes of PPI compounds to increase their potency, selectivity, and bioavailability. In Aim 2, we will determine the selectivity of the compounds for G¿?-SNAP25 interaction compared to other G¿?-interacting proteins. In Aim 3, we will determine the effects of the optimized molecules on neurotransmitter release from hippocampal neurons in culture, and determine whether they synergize with the agonists and antagonists of presynaptic Gi/o-coupled GPCRs. These compounds should allow us to evaluate the importance of G¿?-SNARE interaction for GPCR modulation of exocytosis. They may work in parallel with agonists or antagonists of presynaptic GPCRs, and thus synergize with presynaptic functions, selectively affecting presynaptic but not postsynaptic actions of neurotransmitters. The investigations we propose address a fundamental problem in neuroscience, the molecular mechanisms by which neurotransmitters control exocytosis. These studies may define targets for the development of new therapies that may shed light on the pathological basis of diseases related to secretion and neuromodulation.
描述(由申请人提供):通过调节胞吐作用释放化学递质是许多形式的细胞间通讯的基础,包括激素释放和突触传递。胞吐作用受到复杂的调节,并涉及蛋白质-蛋白质相互作用和膜重塑事件的网络。G蛋白偶联受体(GPCRs)在协调这种复杂的调节中起着核心作用,众所周知,Gi/o偶联GPCRs通过释放G蛋白抑制神经分泌细胞释放递质。亚单位。这种深刻的抑制有可能有助于突触前整合和突触可塑性。这种抑制作用的最佳研究机制是调节Ca 2+通道的电压敏感性。 但是,G?还可以通过结合可溶性N-乙基马来酰亚胺敏感因子附着蛋白受体(SNARE)蛋白以及组装的SNARE复合物来直接抑制Ca 2+进入远端点的神经递质释放。我们已经表明,SNAP 25的C-末端对于抑制递质释放的能力至关重要。我们设计了一种G的测定方法,SNAP 25相互作用,并筛选了一个小的化合物库,这些化合物是基于已知的化学型设计的,这些化学型调节蛋白质-蛋白质相互作用(PPI)的抑制剂和增强剂。在这笔赠款中,我们将 优化抑制剂和增强剂的G?- SNAP 25相互作用在目标1中,我们将对两类PPI化合物进行药物化学优化,以提高其效力、选择性和生物利用度。在目标2中,我们将确定化合物对G?-的选择性。SNAP 25相互作用与其他G?相互作用的蛋白质在目标3中,我们将确定优化的分子对培养的海马神经元的神经递质释放的影响,并确定它们是否与突触前Gi/o偶联GPCR的激动剂和拮抗剂协同作用。这些化合物应该使我们能够评估G的重要性。用于胞吐的GPCR调节的SNARE相互作用。它们可以与突触前GPCR的激动剂或拮抗剂平行工作,从而与突触前功能协同作用,选择性地影响神经递质的突触前而非突触后作用。我们提出的研究解决了神经科学中的一个基本问题,即神经递质控制胞吐作用的分子机制。这些研究可能为开发新疗法确定目标,这些新疗法可能揭示与分泌和神经调节相关的疾病的病理基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HEIDI E HAMM其他文献

HEIDI E HAMM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HEIDI E HAMM', 18)}}的其他基金

Role of Protease Activated Receptor 4 in cerebrovascular dysfunction and dementia
蛋白酶激活受体4在脑血管功能障碍和痴呆中的作用
  • 批准号:
    10287131
  • 财政年份:
    2021
  • 资助金额:
    $ 40.08万
  • 项目类别:
Role of Protease Activated Receptor 4 in cerebrovascular dysfunction and dementia
蛋白酶激活受体4在脑血管功能障碍和痴呆中的作用
  • 批准号:
    10468275
  • 财政年份:
    2021
  • 资助金额:
    $ 40.08万
  • 项目类别:
Cerebrovascular involvement in Alzheimer's Disease: PAR4 Antagonism
阿尔茨海默病的脑血管受累:PAR4 拮抗作用
  • 批准号:
    10212053
  • 财政年份:
    2021
  • 资助金额:
    $ 40.08万
  • 项目类别:
Targeting PAR4 in Thrombotic Disorders:Pharmacogenomic Approach
血栓性疾病中的靶向 PAR4:药物基因组学方法
  • 批准号:
    9900857
  • 财政年份:
    2017
  • 资助金额:
    $ 40.08万
  • 项目类别:
Optimization of modulators of Gbg-SNARE interaction
Gbg-SNARE 相互作用调制器的优化
  • 批准号:
    8856366
  • 财政年份:
    2014
  • 资助金额:
    $ 40.08万
  • 项目类别:
Optimization of modulators of Gbg-SNARE interaction
Gbg-SNARE 相互作用调制器的优化
  • 批准号:
    9085379
  • 财政年份:
    2014
  • 资助金额:
    $ 40.08万
  • 项目类别:
Optimization of PAR4 antagonists for thrombotic disorders
治疗血栓性疾病的 PAR4 拮抗剂的优化
  • 批准号:
    8725756
  • 财政年份:
    2013
  • 资助金额:
    $ 40.08万
  • 项目类别:
Optimization of PAR4 antagonists for thrombotic disorders
治疗血栓性疾病的 PAR4 拮抗剂的优化
  • 批准号:
    8584861
  • 财政年份:
    2013
  • 资助金额:
    $ 40.08万
  • 项目类别:
Screening for allosteric modulators of the protease activated receptor 4
筛选蛋白酶激活受体 4 的变构调节剂
  • 批准号:
    8629339
  • 财政年份:
    2013
  • 资助金额:
    $ 40.08万
  • 项目类别:
Screening for allosteric modulators of the protease activated receptor 4
筛选蛋白酶激活受体 4 的变构调节剂
  • 批准号:
    8742012
  • 财政年份:
    2013
  • 资助金额:
    $ 40.08万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了